Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MYL- 1401O · 1 trial · 1 indication
Tumor measurements were perform by centralized blinded reviewers using RECIST 1.1 criteria. Per RECIST 1.1: Complete Response (CR): Disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm.Partial Response (PR): \>/= 30% decrease sum of the diameters of target lesions from baseline sum diameters. Progressive Disease (PD): \</= 20% increase in the sum of the diameters of target lesions, from the smallest sum on study with at least a 5 mm absolute increase in the sum of all lesions. The appearance of one or more new lesions\* denotes disease progression. Stable Disease (SD): Neither sufficient decrease or increase. Evaluation of Non-Target Lesions Complete Response (CR): Disappearance of all non-target lesions. Non-complete Response/Non-Progressive Disease: Persistence of one or more non-target lesions. Progressive Disease (PD): Substantial, unequivocal progression of existing non-target lesions.
| Arm | Type | Description |
|---|---|---|
| Herceptin© + Taxane | ACTIVE_COMPARATOR | Part 1: Herceptin© (trastuzumab) intravenously+ paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint. Part 2: If SD or PR, CR at cycle 9 (week 24) proceed to Herceptin© (trastuzumab) alone once every 3 weeks until DP or subject withdrawal . |
| MYL- 1401O + Taxane | EXPERIMENTAL | Part 1:MYL-1401O Intravenously + paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint. Part 2: If SD or PR, CR at cycle 9 (week 24) proceed to MYL-1401O alone once every 3 weeks until DP or subject withdrawal. |
| Name | Type | Description |
|---|---|---|
| Trastuzumab | BIOLOGICAL | Trastuzumab 8mg/kg Iv over 90 minutes x 1 then Trastuzumab 6 mg/kg IV over 30 minutes every 3 weeks |
| MYL- 1401O | BIOLOGICAL | MYL-1401O 8mg/kg Iv over 90 minutes x 1 then HERMyl 1401O Trastuzumab 6 mg/kg IV over 30 minutes every 3 weeks |
| Paclitaxel | DRUG | Paclitaxel 80mg/m2 IV over 60 minutes weekly. |
| Docetaxel | DRUG | Docetaxel 75mg/m2 IV over 60 minutes on day 1 of a 3 week cycle |
Inclusion Criteria: Locally recurrent or MBC that is not amenable to curative surgery and/or radiation. Documentation of HER2 gene amplification by fluorescent in situ hybridization (FISH) (as defined by a ratio \>2.0) or documentation of HER2-overexpression by immunohistochemistry (IHC) (defined ...
Top 20 of 92 competitors
MYL-1401O is a monoclonal antibody being developed for the treatment of breast cancer. It is currently in Phase 3 clinical development and is being studied as a first-line treatment for metastatic breast cancer in combination with a taxane.
MYL-1401O is a monoclonal antibody, but its specific molecular target has not been disclosed. It is being studied in combination with a taxane for the first-line treatment of metastatic breast cancer.
MYL-1401O is being developed by Viatris Inc., a company traded on the stock exchange under the ticker symbol VTRS.
MYL-1401O is in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities.
MYL-1401O has one completed Phase 3 clinical trial, identified as NCT02472964. This trial enrolled 500 participants and studied the efficacy and safety of MYL-1401O plus a taxane compared to Herceptin plus a taxane for first-line treatment of metastatic breast cancer.
MYL-1401O is being studied as a potential biosimilar to Herceptin, but it is not the same drug. The Phase 3 trial compared MYL-1401O plus a taxane to Herceptin plus a taxane in patients with metastatic breast cancer.